zintick

Tango Therapeutics TNGX

Tango Therapeutics, Inc. · Nasdaq · Pharmaceutical Preparations

$22.23-2.88%close on Oct. 28, 2026 · volume 3.3M · Yahoo Finance

Price, last 47 sessions

$22.00$24.00$26.00Sept. 2026Oct. 2026
Aug. 24, 2026 to Oct. 28, 2026 · high $27.93 · low $21.75 · SEC filing, placed when SEC released it

Our coverage

Nothing published yet.

Insider buying and selling

DateInsiderTradeSharesAvg. priceValue
Oct. 1, 2026Adam Crystal
President, R&D
Sold
10b5-1 plan
27,000$24.47
$24.45-$25.32
$660,796
Sept. 22, 2026Jessica Newcomb
Principal Accounting Officer
Sold
10b5-1 plan
8,200$24.22
$22.80-$25.17
$198,613
Sept. 1, 2026Adam Crystal
President, R&D
Sold
10b5-1 plan
27,000$22.37$603,909
Aug. 3, 2026Adam Crystal
President, R&D
Sold
10b5-1 plan
27,000$27.24
$26.79-$27.35
$735,517

Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.

Recent SEC filings

All 17 →
  • 8-KOct. 23, 2026, 6:36 a.m. ETView on SEC.gov

    Regulation FD disclosure · Other events · Financial statements and exhibits

    AI summary, unreviewedTango Therapeutics (TNGX) Reports 82% ORR in 2L/3L Pancreatic Cancer With Vopimetostat plus Daraxonrasib, Plans Phase 3 for 1H 2027 and Cuts Workforce 14%

  • 4Oct. 5, 2026, 5:36 p.m. ETView on SEC.gov
  • 4Sept. 24, 2026, 7:41 p.m. ETView on SEC.gov
  • 4Sept. 3, 2026, 4:01 p.m. ETView on SEC.gov
  • SCHEDULE 13G/AAug. 14, 2026, 4:40 p.m. ETView on SEC.gov
  • SCHEDULE 13G/AAug. 14, 2026, 4:13 p.m. ETView on SEC.gov
  • SCHEDULE 13G/AAug. 14, 2026, 11:05 a.m. ETView on SEC.gov
  • SCHEDULE 13G/AAug. 14, 2026, 8:23 a.m. ETView on SEC.gov